162 related articles for article (PubMed ID: 25245943)
1. Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.
Schipani A; Back D; Owen A; Davies G; Khoo S; Siccardi M
Clin Pharmacokinet; 2015 Jan; 54(1):107-16. PubMed ID: 25245943
[TBL] [Abstract][Full Text] [Related]
2. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
[TBL] [Abstract][Full Text] [Related]
3. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D
Clin Pharmacokinet; 2013 Jul; 52(7):583-92. PubMed ID: 23479398
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Stöhr W; Back D; Dunn D; Sabin C; Winston A; Gilson R; Pillay D; Hill T; Ainsworth J; Pozniak A; Leen C; Bansi L; Fisher M; Orkin C; Anderson J; Johnson M; Easterbrook P; Gibbons S; Khoo S; ;
Antivir Ther; 2008; 13(5):675-85. PubMed ID: 18771051
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
Gunda DW; Kasang C; Kidenya BR; Kabangila R; Mshana SE; Kidola J; Kalluvya SE; Kongola GW; Klinker H
PLoS One; 2013; 8(9):e75118. PubMed ID: 24058655
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
7. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
[TBL] [Abstract][Full Text] [Related]
9. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
Funderburg N; Kalinowska M; Eason J; Goodrich J; Heera J; Mayer H; Rajicic N; Valdez H; Lederman MM
PLoS One; 2010 Oct; 5(10):e13188. PubMed ID: 20949133
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
Liyanage M; Nikanjam M; McFadyen L; Vourvahis M; Rogg L; Moye J; Chadwick EG; Jean-Philippe P; Mirochnick M; Whitson K; Bradford S; Capparelli EV; Best BM
Pediatr Infect Dis J; 2022 Nov; 41(11):885-890. PubMed ID: 35980827
[TBL] [Abstract][Full Text] [Related]
13. Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.
Achhra AC; Boyd MA; Law MG; Matthews GV; Kelleher AD; Cooper DA
PLoS One; 2014; 9(6):e99530. PubMed ID: 24968324
[TBL] [Abstract][Full Text] [Related]
14. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
[TBL] [Abstract][Full Text] [Related]
15. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Else LJ; Taylor S; Back DJ; Khoo SH
Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
[TBL] [Abstract][Full Text] [Related]
18. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
[TBL] [Abstract][Full Text] [Related]
19. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]